Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Autor: | Rizwan Haq, Kristina M. Kelley, Meredith Davis, Anita Giobbie-Hurder, Romualdo Barroso-Sousa, Rona S. Carroll, Hilary Donahue, Maria Gargano, Kevin Zhang, Sara M. Tolaney, Hyunju Lee, Le Min, Patrick A. Ott, Ursula B. Kaiser, F. Stephen Hodi, Elizabeth I. Buchbinder |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male endocrine system Cancer Research medicine.medical_specialty endocrine system diseases Combination therapy Immunology 030209 endocrinology & metabolism Gastroenterology Article Thyroiditis Immunomodulation 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Hypothyroidism Cell Line Tumor Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Molecular Targeted Therapy Adverse effect Aged business.industry Thyroid Cancer Middle Aged medicine.disease Thyroid Diseases Immune checkpoint Thyroid disorder Thyrotoxicosis medicine.anatomical_structure Endocrinology 030220 oncology & carcinogenesis Female Thyroid function business Biomarkers |
Zdroj: | Cancer Immunology Research. 5:1133-1140 |
ISSN: | 2326-6074 2326-6066 |
Popis: | Thyroid disorders have emerged as one of the most common immune-related adverse events associated with anti–PD-1 monotherapy or combination anti–PD-1 and anti–CTLA-4 therapy. This study characterizes and compares the evolution of monotherapy and combination therapy-related thyroid disorders. We analyzed the dynamic evolution of thyroid disorders in 45 patients who developed thyroid disorders following treatment with either anti–PD-1 monotherapy or anti–PD-1 and anti–CTLA-4 combination therapy. The patients presented with thyrotoxicosis or hypothyroidism as the initial presentation of their thyroid disorder. Thyrotoxicosis as the initial presentation occurred in the majority of patients (93% and 56% of the patients receiving combination therapy and monotherapy, respectively). The onset pattern of the thyroid disorder was significantly different between the two groups (P = 0.01). Subsequently, 76% and 90% of the patients with thyrotoxicosis evolved to develop hypothyroidism in the combination and monotherapy groups, respectively. In the combination therapy and monotherapy groups, the median times to onset of thyrotoxicosis and hypothyroidism after first treatment were 21 and 63 days, and 31 and 68 days, respectively. The median time for transition from thyrotoxicosis to hypothyroidism was 42 days in both groups. Our study demonstrates that most thyroid disorders induced by either anti–PD-1 or combination anti–PD-1 and anti–CTLA-4 therapy are thyroiditis. The time to onset of thyrotoxicosis after treatment initiation and evolution of thyrotoxicosis to hypothyroidism was short, emphasizing the importance of close monitoring of thyroid function in these patients. Cancer Immunol Res; 5(12); 1133–40. ©2017 AACR. |
Databáze: | OpenAIRE |
Externí odkaz: |